Table 3.

Clinical picture and laboratory findings

Pt	Comorbidities	OT	NIVS*	Treatment at biopsy time†	Blood lymphopenia‡	High serum IL-6§	High D-dimer levelsll	Increased BAL lymphocytes**
1	No	No	No	Hydroxychloroquine Ritonavir/darunavir Corticosteroids	Yes	No	No	Yes
2	No	Yes	Yes	Hydroxychloroquine Ritonavir/darunavir Corticosteroids Enoxaparin	Yes	Yes	No	Yes
3	Hypertension, hyperlipidemia, GERD	No	No	Hydroxychloroquine Corticosteroids Enoxaparin	No	No	No	Yes
4	Hypertension, obesity, OSA	Yes	Yes	Hydroxychloroquine Ritonavir/darunavir Corticosteroids Enoxaparin	No	No	Yes	No
5	Hyperlipidemia	No	No	Hydroxychloroquine Ritonavir/darunavir Corticosteroids Enoxaparin	No	No	No	n/a
5	Hyperlipidemia	No	No	Hydroxychloroquine Ritonavir/darunavir Corticosteroids Enoxaparin	No	No	No	n/a
6	No	Yes	No	Hydroxychloroquine Ritonavir/darunavir Corticosteroids Enoxaparin	No	No	No	No
7	No	No	No	Hydroxychloroquine Ritonavir/darunavir Corticosteroids	No	No	No	Yes
8	Hypertension	Yes	Yes	Hydroxychloroquine Ritonavir/darunavir Corticosteroids Enoxaparin Canakinumab	No	No	Yes	No
9	No	No	No	Corticosteroids Enoxaparin	No	No	Yes	No
10	Hyperlipidemia	Yes	No	Corticosteroids Enoxaparin	No	No	Yes	No
11	No	No	No	Corticosteroids Enoxaparin	No	n/a	Yes	n/a
12		Psoriasis	No	Corticosteroids Enoxaparin	No	No	No	n/a

Pt, patient; OT, oxygen therapy; NIVS; noninvasive ventilator support; BAL, bronchoalveolar lavage; GERD, gastroesophageal reflux disease; OSA, obstructive sleep apnea; n/a, not available.

^*All patients did not need invasive ventilation and recovered completely.

^†All patients received corticosteroids at biopsy time (30–100 mg prednisone equivalent a day); all patients receiving enoxaparin were treated with standard prophylaxis dose.

^‡Lymphopenia was defined as lymphocytes count <1.00 ×10⁹/L at biopsy time.

^§Normal value for serum IL-6 was <5.90 pg/mL; significantly high IL-6 levels were defined as IL-6 <40 pg/mL at biopsy time.

^llCutoff value for D-dimer was <500 µg/mL FEU.

^**BAL lymphocytosis was defined as lymphocytes <20%.